# Bradykinin Mediated Angioedema Market > ブラジキニン媒介性浮腫市場調査報告書 タイプ別（遺伝性浮腫、後天性浮腫、特発性浮腫）、治療オプション別（C1-インヒビター置換療法、ブラジキニンB2受容体拮抗薬、カリナイト療法、抗線溶薬）、投与経路別（皮下、静脈内、経口）、患者の人口統計別（小児患者、成人患者、高齢者患者）および地域別（北米、ヨーロッパ、南米、アジア太平洋、中東およびアフリカ） - 成長と産業予測 2025年から2035年 - **Forecast Period:** 2025 - 2035 - **CAGR:** 11.62% - **2024:** $ 1.15 Billion - **2025:** $ 1.29 Billion - **2035:** $ 3.87 Billion - **Key Players:** Takeda Pharmaceutical Company Limited (JP), CSL Behring LLC (US), Pharming Group N.V. (NL), Sobi AB (SE), BioCryst Pharmaceuticals, Inc. (US), Eisai Co., Ltd. (JP), Grifols S.A. (ES), Amgen Inc. (US) **Report ID:** MRFR/HC/34260-HCR · **Pages:** 128 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** August 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/bradykinin-mediated-angioedema-market-36162 --- ## Market Summary ## **Bradykinin Mediated Angioedema Market Overview** As per MRFR analysis, the Bradykinin Mediated Angioedema Market Size was estimated at 1.15 (USD Billion) in 2024. The Bradykinin Mediated Angioedema Market Industry is expected to grow from 1.29 (USD Billion) in 2025 to 3.47 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 11.62% during the forecast period (2025 - 2034). ### **Key Bradykinin Mediated Angioedema Market Trends Highlighted** The Bradykinin Mediated Angioedema Market is significantly influenced by several key market drivers. An increasing awareness of the disorder has led to a rise in early diagnosis and treatment options. Enhancements in medical research have improved the understanding of angioedema, promoting the development of targeted therapies. Additionally, the growing prevalence of underlying conditions such as hereditary angioedema and increased access to healthcare services are facilitating market expansion. Pharmaceutical advancements are also pushing the boundaries of treatment modalities, further driving the market. Opportunities in this market are abundant, particularly in the development of innovative therapies and products targeting various patient demographics. The rise of personalized medicine opens new avenues for customized treatment solutions. Collaborations between pharmaceutical companies and research institutions can accelerate drug discovery processes. Expanding geographical presence in emerging markets represents another significant opportunity, as these regions often have unmet medical needs and a growing patient population. The establishment of educational programs focused on angioedema can help in raising awareness, leading to better patient outcomes and market growth. In recent times, there has been a noticeable trend towards the development of biologic drugs, which are showing promise in effectively managing symptoms of bradykinin-mediated angioedema. Advancements in biotechnology are contributing to this trend, along with a shift toward chronic disease management models. Digital health solutions, including telemedicine and mobile applications for monitoring symptoms, are gaining traction. These trends indicate a shift in how healthcare is delivered, making it more accessible and patient-centered. As the market evolves, these dynamics will likely shape its future direction, offering new potential pathways for growth and innovation. Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Bradykinin Mediated Angioedema Market Drivers** ### **Increasing Awareness and Diagnosis of Bradykinin Mediated Angioedema** As the prevalence of bradykinin mediated angioedema becomes more recognized, both healthcare providers and patients are gaining a better understanding of this condition. There has been an evident shift towards improving diagnosis rates, identifying symptoms early, and advocating for timely treatment. Enhanced education and awareness campaigns from health organizations contribute significantly to this shift. As medical professionals become more informed about the various manifestations of angioedema, they are better equipped to identify bradykinin mediated cases. This growing awareness extends to patients, who are increasingly educated about their conditions through support groups, online resources, and healthcare platforms. Consequently, more individuals are seeking medical advice, leading to a higher rate of diagnosis and treatment. This trend is a crucial driver for the Bradykinin Mediated Angioedema Market Industry as it translates into increased demand for healthcare services, diagnostic tools, and effective therapies. With more patients being diagnosed, pharmaceutical companies are prompted to invest in the development of specialized medications, further fueling market growth. The heightened focus on research and development to understand the pathophysiological mechanisms underlying this condition is also pivotal. Importantly, as more advancements are made in treatments, physicians are likely to prescribe these innovative solutions, which will be highly beneficial for patient outcomes. Thus, increasing awareness not only plays a key role in patient diagnosis but also drives the innovation and growth of the Bradykinin Mediated Angioedema Market Industry, fostering a cycle that enhances overall healthcare standards and improves life quality for patients experiencing this condition. ### **Technological Advancements in Pharmaceutical Development** The Bradykinin Mediated Angioedema Market Industry is significantly benefiting from profound advancements in technology, particularly in pharmaceutical research and product development. Innovations in biotechnology and drug formulation techniques have led to the introduction of more effective treatments for bradykinin mediated angioedema, enhancing patient care. The development of monoclonal antibodies, small molecules, and new biologics specifically targeting the underlying mechanisms of bradykinin release exemplifies the forward momentum in this field. Furthermore, improved drug delivery systems are ensuring better patient compliance and therapeutic outcomes, making these treatments more accessible and efficient. Such technological breakthroughs are vital in expanding the available treatment options, which, in turn, supports the growth of the Bradykinin Mediated Angioedema Market. ### **Rising Incidence of Angioedema Cases** The growing incidence of angioedema cases globally is a major driver for the Bradykinin Mediated Angioedema Market Industry. Factors such as environmental changes, dietary habits, and increased exposure to allergens contribute to the rise in cases. This upward trend necessitates enhanced healthcare initiatives, expanding the market for targeted therapies and treatments for patients suffering from this condition. As more individuals experience symptoms and seek medical assistance, healthcare providers are more inclined to focus on providing effective solutions, leading to market growth. ## ** ****Bradykinin Mediated Angioedema Market Segment Insights** ### **Bradykinin Mediated Angioedema Market Type Insights** The Bradykinin Mediated Angioedema Market is witnessing significant growth, with a market valuation of 0.93 USD Billion in 2023 and expected to reach 2.5 USD Billion by 2032, driven by rising awareness and improved diagnostics. The market segmentation around Type prominently features Hereditary Angioedema, Acquired Angioedema, and Idiopathic Angioedema. Among these, [Hereditary Angioedema](../../../reports/hereditary-angioedema-therapeutics-market-12163) holds a majority market share, valued at 0.4 USD Billion in 2023, and is projected to grow substantially to 1.05 USD Billion by 2032, highlighting its dominance due to genetic predispositions and increasing patient identification. This sub-segment is particularly significant as it emphasizes the need for targeted therapies and ongoing patient management strategies. Acquired Angioedema, while smaller in comparison, reflects a substantial market presence, with a valuation of 0.3 USD Billion in 2023 and expected growth to 0.8 USD Billion by 2032. The challenges surrounding the identification of triggers and underlying conditions contribute to its relevance in the market, making the development of therapeutic options increasingly important. Lastly, Idiopathic Angioedema, which accounted for 0.23 USD Billion in 2023 and aims for a future valuation of 0.65 USD Billion, is the least dominant type. However, it presents unique challenges due to its unpredictable nature, leading to a notable opportunity for pharmaceutical advancements and improved treatment strategies. The Bradykinin Mediated Angioedema Market data reflects a balanced yet complex interplay of these segments, with varying growth drivers, including heightened research initiatives and patient advocacy groups fostering a conducive environment for market expansion. Understanding this market segmentation allows stakeholders to tailor their approaches to meet the varying needs of each type effectively while capitalizing on the growth potential and complexities inherent in the treatment landscape. As such, the industry faces opportunities and challenges that influence the development of effective therapies tailored for specific Angioedema types, ensuring that patient outcomes continue to improve as the market evolves. Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Bradykinin Mediated Angioedema Market Treatment Options Insights** The Bradykinin Mediated Angioedema Market, focusing on Treatment Options, shows a robust growth trajectory, with the market valued at 0.93 billion USD in 2023. By 2032, this market is expected to grow significantly. The Treatment Options segment is driven by an increasing prevalence of Bradykinin Mediated Angioedema, with key therapies such as C1-Inhibitor Replacement Therapy playing a pivotal role owing to its effectiveness in managing acute attacks. Bradykinin B2 Receptor Antagonists are also essential, showcasing a significant demand due to their targeted action in slowing down symptoms related to angioedema. Additionally, Kalinate Therapy is garnering attention as it presents opportunities for enhanced patient outcomes. Antifibrinolytic Agents remain crucial within this market, offering therapeutic benefits that complement other treatment modalities. Overall, the Bradykinin Mediated Angioedema Market revenue illustrates a clear alignment between growing treatment needs and innovative drug development strategies, emphasizing the importance of each therapy in providing effective management of the disorder amidst evolving patient care standards. ### **Bradykinin Mediated Angioedema Market Route of Administration Insights** The Bradykinin Mediated Angioedema Market is experiencing significant growth, particularly in the Route of Administration segment, which plays a critical role in treatment efficacy and patient compliance. In 2023, the market was valued at 0.93 billion USD and is projected to expand substantially in the coming years. The market sees a strong emphasis on various methods of administration, including Subcutaneous, Intravenous, and Oral, each catering to different patient needs. Subcutaneous administration is noted for its ease of use and ability to improve patient adherence, making it a preferred choice among healthcare providers. Intravenous administration, albeit less common, offers rapid action for acute cases and is vital in clinical settings. The Oral route, with its convenience and patient-friendly nature, continues to gain traction, appealing particularly to home care settings. These various routes contribute to the segmentation of the Bradykinin Mediated Angioedema Market, which is crucial for targeted therapies tailored to individual patient profiles. The growth in this segment is driven by an increasing prevalence of bradykinin-mediated conditions, evolving treatment paradigms, and ongoing research into improving administration methods while enhancing patient experience and outcomes. The Bradykinin Mediated Angioedema Market data reveals promising trends around these administration routes, highlighting their potential to meet diverse healthcare needs. ### **Bradykinin Mediated Angioedema Market Patient Demographics Insights** The Bradykinin Mediated Angioedema Market, valued at 0.93 billion USD in 2023, showcases a diverse Patient Demographics segment that includes Pediatric, Adult, and Geriatric Patients. Each group presents unique needs and characteristics, playing a crucial role in shaping the overall market dynamics. Pediatric Patients often face challenges with diagnosis and treatment adherence, making this demographic vital for future treatment innovations. Meanwhile, Adult Patients typically dominate the market due to the higher prevalence of bradykinin-mediated conditions within this age group, driven by lifestyle factors and genetic predispositions. The Geriatric Patients segment is also significant as it is increasingly impacted by this condition alongside age-related health issues, creating a demand for tailored therapeutic solutions. These demographics collectively contribute to the Bradykinin Mediated Angioedema Market growth as the industry responds to their specific treatment requirements and associated healthcare trends. Overall, the market exhibits a steady increase in interest and investment, emphasizing the importance of understanding these patient segments for future strategies and developments in the industry.With an expected continued expansion, the market is poised to address escalating healthcare needs responsibly and effectively. ### **Bradykinin Mediated Angioedema Market Regional Insights** The Bradykinin Mediated Angioedema Market revenue is witnessing substantial growth across different regions, with North America holding a significant market share of 0.42 USD Billion in 2023, projected to increase to 1.05 USD Billion by 2032. This dominance can be attributed to advanced healthcare infrastructure and a high prevalence of angioedema cases. Europe follows as another key region, with market values of 0.25 USD Billion in 2023 and 0.65 USD Billion in 2032, benefiting from a strong regulatory framework and research initiatives. The APAC region, though smaller, shows promising growth potential, escalating from 0.15 USD Billion in 2023 to 0.45 USD Billion by 2032, driven by rising healthcare awareness and investments in treatment options. South America and MEA represent the emerging markets in the Bradykinin Mediated Angioedema Market industry, with values of 0.06 USD Billion and 0.05 USD Billion in 2023, respectively, reflecting a growth trajectory as healthcare access improves. These regions present significant opportunities to tap into increasing demand for effective treatments as more awareness of this condition grows. Bradykinin Mediated Angioedema Market statistics indicate a clear trend toward increased investments, highlighting the importance of continuously expanding healthcare access and innovation across these diverse regions. Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Bradykinin Mediated Angioedema Market Key Players and Competitive Insights** The Bradykinin Mediated Angioedema Market is characterized by a dynamic competitive landscape, driven by the increasing prevalence of angioedema conditions and the growing understanding of bradykinin's role in these diseases. As research advances, companies are focusing on the development of innovative therapeutic options that cater to the specific needs of patients suffering from angioedema.  The market includes a variety of stakeholders ranging from pharmaceutical giants to specialized biotechnology firms, all vying for a significant share. Companies are employing strategies such as collaborations, mergers, and acquisitions to enhance their product portfolios and extend their market reach. The landscape is also marked by intense competition where product differentiation and effective marketing strategies play crucial roles in capturing consumer attention. Takeda Pharmaceutical Company holds a prominent position in the Bradykinin Mediated Angioedema Market, showcasing its strengths through a robust pipeline of products and research initiatives targeted specifically at treating angioedema. The company is recognized for its commitment to patient-centric solutions, which is reflected in its innovative approaches to treatment development. Takeda's strategy emphasizes the importance of addressing patient needs and improving health outcomes, enabling it to maintain a competitive edge in the market.  Additionally, its extensive network and experience in managing complex therapeutic areas bolster its operational capabilities and market presence. By investing in research and development, Takeda continually seeks to enhance its therapeutic offerings, solidifying its reputation in the bradykinin-mediated angioedema segment. Novo Nordisk has also established itself as a key player in the Bradykinin Mediated Angioedema Market, bringing valuable expertise and resources to the table. The company is known for its strong focus on innovation, particularly in developing effective therapies that manage rare and chronic conditions like bradykinin-mediated angioedema. Novo Nordisk adopts a holistic approach to treatment by incorporating advancements in biotechnology and leveraging its extensive knowledge of patient care. Its commitment to research allows for the continuous evolution of its product offerings, positioning the company effectively against its competitors.  Furthermore, Novo Nordisk's strategic partnerships and collaborations enhance its ability to introduce novel solutions to the market, ensuring it meets the demands and needs of patients suffering from angioedema in an increasingly competitive environment. ### **Key Companies in the Bradykinin Mediated Angioedema Market Include** - Takeda Pharmaceutical Company - Novo Nordisk - Biocryst Pharmaceuticals - GSK - Bayer AG - Pfizer Inc - CSL Limited - [**Amgen Inc**](https://www.amgen.com/products) - Regeneron Pharmaceuticals - Roche Holding AG - Eli Lilly and Company - Merck and Co - Sanofi - AstraZeneca - Shire plc ## Bradykinin Mediated Angioedema Market Industry Developments - **Q2 2025: Pharvaris Presents Promising Data on Deucrictibant for Bradykinin-Mediated Angioedema at EAACI Congress 2025** Pharvaris presented new clinical data on deucrictibant, an oral bradykinin B2 receptor antagonist, at the EAACI Congress 2025, showing significant attack reduction and improved quality of life for hereditary angioedema patients. The company also announced advancement into Phase 3 trials for both prophylactic and on-demand treatment indications. - **Q2 2025: Pharvaris AGM 2025: A Pivotal Moment for Braking into the Angioedema Market** Pharvaris N.V. announced that its lead drug candidate, deucrictibant, is approaching pivotal clinical readouts and regulatory milestones, with the company preparing for its June 27, 2025 Annual General Meeting. The oral therapy targets both hereditary and acquired bradykinin-mediated angioedema, with Phase 3 trials underway. - **Q1 2025: Pharvaris Outlines 2025 Strategic Priorities** Pharvaris announced the initiation of CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis against hereditary angioedema attacks, and confirmed ongoing preparations for regulatory submission and commercialization pending trial results. ## **Bradykinin Mediated Angioedema Market Segmentation Insights** ### **Bradykinin Mediated Angioedema Market Type Outlook** - Hereditary Angioedema - Acquired Angioedema - Idiopathic Angioedema ### **Bradykinin Mediated Angioedema Market Treatment Options Outlook** - C1-Inhibitor Replacement Therapy - Bradykinin B2 Receptor Antagonists - Kalinate Therapy - Antifibrinolytic Agents ### **Bradykinin Mediated Angioedema Market Route of Administration Outlook** - Subcutaneous - Intravenous - Oral ### **Bradykinin Mediated Angioedema Market Patient Demographics Outlook** - Pediatric Patients - Adult Patients - Geriatric Patients ### **Bradykinin Mediated Angioedema Market Regional Outlook** - North America - Europe - South America - Asia Pacific - Middle East and Africa ## Market Drivers ### Increased Research Funding {"k"=>"研究資金の増加", "v"=>"ブラジキニン媒介性血管浮腫の研究資金の配分は、ブラジキニン媒介性血管浮腫市場の重要な推進要因です。政府や民間団体は、血管浮腫の根本的なメカニズムを理解し、効果的な治療法を開発することを目的とした研究にますます投資しています。この資金の流入は、革新のペースを加速させ、新しい治療薬の発見につながると期待されています。さらに、研究が進むにつれて、新しいバイオマーカーの特定が診断精度と治療効果を向上させる可能性があります。この分野の知識を進展させるための取り組みは、ブラジキニン媒介性血管浮腫市場の成長軌道を強化する可能性が高いです。"} ### Rising Incidence of Angioedema {"k"=>"血管浮腫の発生率の上昇", "v"=>"ブラジキニン媒介性血管浮腫の有病率の増加は、ブラジキニン媒介性血管浮腫市場の顕著な推進要因です。最近の研究によると、遺伝性血管浮腫の発生率は約50,000人に1人であり、獲得型の形態もますます認識されるようになっています。この症例の増加は、効果的な治療オプションを必要とし、市場の成長を促進します。状態に対する認識が広がるにつれて、医療提供者は患者を診断し治療する可能性が高まり、市場の拡大にさらに寄与します。増加する患者人口は、革新的な治療法への需要を促進し、ブラジキニン媒介性血管浮腫市場における研究開発への投資の増加につながると予想されます。"} ### Growing Patient Advocacy Groups {"k"=>"患者擁護団体の増加", "v"=>"ブラジキニン媒介性血管浮腫に特化した患者擁護団体の出現は、ブラジキニン媒介性血管浮腫市場内での認識と支援を促進しています。これらの組織は、患者や医療専門家にこの状態について教育する重要な役割を果たし、適時の診断と治療を促進します。彼らの認識を高める努力は、より多くの人々が医療支援を求めるため、治療法への需要の増加につながる可能性があります。さらに、これらの団体はしばしば製薬会社と協力して臨床試験を促進し、新しい治療法の開発を加速させることができます。患者擁護の影響は、ブラジキニン媒介性血管浮腫市場の可視性を高める可能性が高いです。"} ### Advancements in Therapeutic Options {"k"=>"治療オプションの進展", "v"=>"ブラジキニン媒介性血管浮腫に対する治療アプローチの革新は、ブラジキニン媒介性血管浮腫市場に大きな影響を与えています。C1インヒビター置換療法やブラジキニン受容体拮抗薬などの新しい治療法の導入は、治療のパラダイムを変革しました。これらの進展は、患者の結果を改善するだけでなく、市場全体の景観を向上させます。例えば、新薬の承認は治療オプションの急増をもたらし、多様な患者のニーズに応えています。市場が進化し続ける中で、標的療法の開発はさらなる投資を引き付ける可能性が高く、ブラジキニン媒介性血管浮腫市場内での成長を促進します。"} ### Regulatory Incentives for Drug Development {"k"=>"薬剤開発のための規制インセンティブ", "v"=>"規制当局は、ブラジキニン媒介性血管浮腫の治療法の開発に対してますますインセンティブを提供しており、これはブラジキニン媒介性血管浮腫市場の重要な推進要因となっています。希少疾病用医薬品の指定や迅速承認などの取り組みは、製薬会社がこのニッチ市場に投資することを促すために設計されています。これらの規制フレームワークは、新しい治療法を市場に投入する際の時間とコストを削減するだけでなく、投資家にとってこの分野の魅力を高めます。より多くの企業が市場に参入するにつれて、競争環境は進化し、ブラジキニン媒介性血管浮腫に苦しむ患者のための治療オプションが広がる可能性が高いです。"} ## Future Outlook ブラジキニン媒介性浮腫市場は、2025年から2035年まで11.62%のCAGRで成長すると予測されており、意識の高まり、革新的な治療法、患者人口の増加が推進力となっています。 2035年までに、市場は大幅な成長を達成し、革新的な治療ソリューションのリーダーとしての地位を確立する見込みです。 ## Segment Insights ### タイプ別：遺伝性血管浮腫（最大）対 獲得性血管浮腫（最も成長している） ブラジキニン媒介血管浮腫市場において、さまざまなタイプの血管浮腫の市場シェアの分布は、遺伝性血管浮腫の顕著な優位性を示しています。このセグメントは、人口の間での認識と診断率の向上、遺伝的条件に特化した治療オプションの進展により、最大の市場シェアを保持し続けています。一方、獲得性血管浮腫は急速に出現しており、その異なる病因や引き金の認識が高まることで、医療提供者の間で注目を集め、研究や治療の機会が拡大しています。 遺伝性血管浮腫（支配的）対 獲得性血管浮腫（新興） 遺伝性血管浮腫は、その遺伝的特性と、この慢性疾患に対応する特定の治療法を含む確立された治療プロトコルにより、ブラジキニン媒介血管浮腫市場内で支配的なセグメントとして残っています。患者はしばしば発作を防ぐために長期的な管理を必要とし、これが専門的な治療の需要を維持しています。一方、獲得性血管浮腫は、状態の臨床理解と診断の向上によって推進される重要なセグメントとして出現しています。薬剤や関連疾患などのさまざまな要因に起因する症例の増加は、医療システムが獲得症例に対する特化した介入により多くの焦点を当てることを促し、革新的な治療法の開発を促進する競争的な環境を形成しています。 ### 治療オプション別：C1-インヒビター置換療法（最大）対 ブラジキニンB2受容体拮抗薬（最も成長している） ブラジキニン媒介血管浮腫市場において、市場シェアの分布は、C1-インヒビター置換療法が最大のセグメントとして位置づけられていることを示しており、全体の市場のかなりの部分を占めています。この確立された地位は、C1インヒビターのレベルを回復する効果に起因しており、臨床医や患者の間で好まれる選択肢となっています。一方、ブラジキニンB2受容体拮抗薬は急速に注目を集めており、ブラジキニン受容体を直接標的とする新しいメカニズムにより、最も成長している治療オプションとして浮上しています。このセグメント内の成長傾向は、ブラジキニン媒介血管浮腫市場に対する認識の高まりや革新的な治療アプローチによって顕著に影響を受けています。血管浮腫の発生率の上昇、薬剤の製剤の進展、新しい治療法の臨床試験の拡大などの要因が、既存および新興の治療オプションの成長に寄与しています。患者の結果を改善することを目的とした治療プロトコルや支援ガイドラインの拡充は、臨床実践におけるこれらの治療法の採用をさらに促進しています。 C1-インヒビター置換療法（支配的）対 ブラジキニンB2受容体拮抗薬（新興） C1-インヒビター置換療法は、その長年の使用と確立された効果により、ブラジキニン媒介血管浮腫市場における支配的な治療オプションとして認識されています。これは、患者の欠乏したC1インヒビターを効果的に置き換え、状態の根本的な原因に対処します。この治療は急性および予防的な設定で好まれることが多く、治療レジメンの主力となっています。対照的に、ブラジキニンB2受容体拮抗薬は、ブラジキニン受容体を標的とする新興の治療クラスを表しており、異なる作用機序を提供します。彼らの急速な開発は、標的療法への関心の高まりを強調し、従来の治療法に十分に反応しない可能性のある患者に対する潜在的な代替手段を提供します。進行中の研究と臨床試験は、今後数年で市場での存在感を大幅に高めることが期待されています。 ### 投与経路別：皮下（最大）対 静脈内（最も成長している） ブラジキニン媒介血管浮腫市場において、投与経路は治療の選好と効果において重要な役割を果たします。皮下投与は、使いやすさ、患者の遵守、治療薬の効果的な提供により、現在最大のシェアを保持しています。静脈内投与は、シェアは低いものの、急性のシナリオにおける迅速な作用の発現により注目を集めており、重度の症状を持つ患者のセグメントに対応しています。 投与方法：皮下（支配的）対 静脈内（新興） ブラジキニン媒介血管浮腫市場における治療の皮下投与経路は支配的であり、患者にとってより簡単で侵襲性の少ない選択肢を提供し、自宅での使用シナリオに適しています。この方法により、個人は専門的な監督を最小限に抑えて自分の状態を管理できます。一方、静脈内投与は、急性の血管浮腫エピソードで即時の緩和を必要とする患者にとって重要な代替手段として出現しています。この方法は、薬剤が迅速に血流に届けられることを保証し、迅速な効果をもたらし、生命を脅かす状況において重要です。 ### 患者の人口統計別：成人患者（最大）対 小児患者（最も成長している） ブラジキニン媒介血管浮腫市場において、人口統計の分布は、成人患者が最大のセグメントを構成していることを示しており、これはこのタイプの血管浮腫を引き起こす慢性疾患の有病率が高いことを反映しています。一方、小児患者は、若年層におけるブラジキニン媒介条件の認識の高まりと診断の改善、子供向けの治療オプションの向上により、最も成長しているセグメントを代表しています。医療提供者が早期介入に焦点を当てる中で、小児セグメントでは報告された症例が大幅に増加しています。この成長は、子供の健康に関する洞察を改善するための活動や、小児人口における血管浮腫の理解に専念した研究への関与の高まりによっても促進されています。この変化は、この状態を管理するための多様な年齢層に特化した治療アプローチの重要性を強調しています。 成人患者（支配的）対 高齢者患者（新興） 成人患者は、主に血管浮腫の症状を悪化させる可能性のある健康状態の既存のリスクや高い感受性により、ブラジキニン媒介血管浮腫市場を支配しています。成人の人口統計は、製薬開発の主要な焦点として位置づけられ、治療の進展は彼らのニーズに広く対応しています。対照的に、高齢者患者は、加齢に伴う健康の複雑さにより重要な人口統計として浮上しています。現在は市場シェアが小さいかもしれませんが、非典型的な血管浮腫の課題の認識が高まり、高齢者向けの特化した治療オプションの必要性が彼らの市場での存在感を強化する可能性があります。医療研究が進化するにつれて、高齢者患者に対する特化した治療法は、加齢に関連する独自の反応や相互作用に対処する上で重要になるでしょう。 ## Regional Market Share Analysis ### North America : Leading Market for Treatments North America is the largest market for Bradykinin Mediated Angioedema Market, accounting for approximately 60% of the global market share. The region's growth is driven by increasing awareness of the condition, advancements in treatment options, and supportive regulatory frameworks. The FDA's approval of new therapies has catalyzed market expansion, with a growing demand for effective management solutions. The United States is the primary contributor, with significant investments from key players like Takeda Pharmaceutical Company Limited and BioCryst Pharmaceuticals, Inc. Canada also plays a vital role, focusing on improving healthcare access and treatment options. The competitive landscape is characterized by a mix of established companies and emerging players, fostering innovation and collaboration in the sector. ### Europe : Emerging Market with Potential Europe is witnessing a significant rise in the Bradykinin Mediated Angioedema Market, holding approximately 25% of the global share. The region's growth is fueled by increasing patient awareness, advancements in biotechnology, and supportive healthcare policies. Regulatory bodies are actively promoting research and development, which is expected to enhance treatment availability and accessibility across member states. Leading countries such as Germany, France, and the UK are at the forefront, with a robust presence of key players like Pharming Group N.V. and Sobi AB. The competitive landscape is evolving, with collaborations between pharmaceutical companies and research institutions aimed at developing innovative therapies. The European Medicines Agency continues to support initiatives that enhance treatment options for patients. ### Asia-Pacific : Rapidly Evolving Healthcare Sector The Asia-Pacific region is emerging as a significant player in the Bradykinin Mediated Angioedema Market, accounting for about 10% of the global share. The growth is driven by increasing healthcare expenditure, rising awareness of rare diseases, and the introduction of innovative therapies. Countries like Japan and Australia are leading the charge, supported by favorable regulatory environments that encourage research and development in this area. Japan is home to key players such as Eisai Co., Ltd., while Australia is witnessing a surge in clinical trials and partnerships aimed at enhancing treatment options. The competitive landscape is characterized by a mix of local and international companies, fostering a collaborative environment for innovation. As the region continues to develop, the demand for effective management solutions is expected to rise significantly. ### Middle East and Africa : Untapped Market Opportunities The Middle East and Africa region is currently the smallest market for Bradykinin Mediated Angioedema Market, holding approximately 5% of the global share. However, the region presents untapped opportunities for growth, driven by increasing healthcare investments and a rising prevalence of rare diseases. Governments are beginning to recognize the importance of addressing these conditions, leading to improved healthcare policies and funding for research initiatives. Countries like South Africa and the UAE are emerging as key players in the market, with a growing interest from international pharmaceutical companies. The competitive landscape is still developing, with local firms collaborating with global entities to enhance treatment availability. As awareness increases, the demand for effective therapies is expected to grow, paving the way for future market expansion. ## Competitive Benchmarking The Bradykinin Mediated Angioedema Market is characterized by a dynamic competitive landscape, driven by increasing awareness of the condition and advancements in therapeutic options. Key players such as Takeda Pharmaceutical Company Limited (Japan), BioCryst Pharmaceuticals, Inc. (US), and Pharming Group N.V. (Netherlands) are at the forefront, each adopting distinct strategies to enhance their market presence. Takeda (Japan) focuses on innovation through the development of novel therapies, while BioCryst Pharmaceuticals, Inc. (US) emphasizes strategic partnerships to bolster its research capabilities. Pharming Group N.V. (Netherlands) appears to be concentrating on expanding its global footprint, particularly in emerging markets, thereby shaping a competitive environment that is increasingly collaborative yet fiercely competitive.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The market structure is moderately fragmented, with a mix of established players and emerging biotech firms. This fragmentation allows for diverse approaches to treatment and patient care, while the collective influence of key players drives innovation and competitive differentiation. In August Takeda Pharmaceutical Company Limited (Japan) announced a strategic collaboration with a leading research institution to accelerate the development of its next-generation therapies for angioedema. This partnership is likely to enhance Takeda's research capabilities and expedite the introduction of innovative treatments, positioning the company as a leader in the therapeutic landscape. In September BioCryst Pharmaceuticals, Inc. (US) launched a new digital platform aimed at improving patient engagement and adherence to treatment protocols. This initiative not only reflects the company's commitment to patient-centric care but also indicates a broader trend towards digital transformation in the healthcare sector, which may enhance treatment outcomes and patient satisfaction. In July Pharming Group N.V. (Netherlands) secured regulatory approval for its latest product aimed at treating hereditary angioedema, marking a significant milestone in its product pipeline. This approval is expected to strengthen Pharming's market position and expand its therapeutic offerings, potentially increasing its share in the competitive landscape. As of October current trends in the Bradykinin Mediated Angioedema Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing supply chain reliability. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological advancements and innovative treatment solutions, underscoring the importance of agility and responsiveness in a rapidly changing market. ## Recent News & Developments - **Q2 2025: Pharvaris Presents Promising Data on Deucrictibant for Bradykinin-Mediated Angioedema at EAACI Congress 2025** Pharvaris presented new clinical data on deucrictibant, an oral bradykinin B2 receptor antagonist, at the EAACI Congress 2025, showing significant attack reduction and improved quality of life for hereditary angioedema patients. The company also announced advancement into Phase 3 trials for both prophylactic and on-demand treatment indications. - **Q2 2025: Pharvaris AGM 2025: A Pivotal Moment for Braking into the Angioedema Market** Pharvaris N.V. announced that its lead drug candidate, deucrictibant, is approaching pivotal clinical readouts and regulatory milestones, with the company preparing for its June 27, 2025 Annual General Meeting. The oral therapy targets both hereditary and acquired bradykinin-mediated angioedema, with Phase 3 trials underway. - **Q1 2025: Pharvaris Outlines 2025 Strategic Priorities** Pharvaris announced the initiation of CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis against hereditary angioedema attacks, and confirmed ongoing preparations for regulatory submission and commercialization pending trial results. ## Report Scope | MARKET SIZE 2024 | 1.154(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 1.288(USD Billion) | | MARKET SIZE 2035 | 3.868(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 11.62% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Takeda Pharmaceutical Company Limited (JP), CSL Behring LLC (US), Pharming Group N.V. (NL), Sobi AB (SE), BioCryst Pharmaceuticals, Inc. (US), Eisai Co., Ltd. (JP), Grifols S.A. (ES), Amgen Inc. (US) | | Segments Covered | Type, Treatment Options, Route of Administration, Patient Demographics, Regional | | Key Market Opportunities | Advancements in targeted therapies and personalized medicine enhance treatment options in the Bradykinin Mediated Angioedema Market. | | Key Market Dynamics | Rising demand for targeted therapies drives innovation and competition in the Bradykinin Mediated Angioedema market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the projected market valuation for Bradykinin Mediated Angioedema by 2035?** A: The projected market valuation for Bradykinin Mediated Angioedema is expected to reach 3.868 USD Billion by 2035. **Q: What was the market valuation for Bradykinin Mediated Angioedema in 2024?** A: The market valuation for Bradykinin Mediated Angioedema was 1.154 USD Billion in 2024. **Q: What is the expected CAGR for the Bradykinin Mediated Angioedema Market during the forecast period 2025 - 2035?** A: The expected CAGR for the Bradykinin Mediated Angioedema Market during the forecast period 2025 - 2035 is 11.62%. **Q: Which companies are key players in the Bradykinin Mediated Angioedema Market?** A: Key players in the Bradykinin Mediated Angioedema Market include Takeda Pharmaceutical Company Limited, CSL Behring LLC, and Pharming Group N.V. **Q: What are the main types of angioedema segments in the market?** A: The main types of angioedema segments include Hereditary Angioedema, Acquired Angioedema, and Idiopathic Angioedema. **Q: What was the market size for Hereditary Angioedema in 2024?** A: The market size for Hereditary Angioedema was 0.462 USD Billion in 2024. **Q: What treatment options are available for Bradykinin Mediated Angioedema?** A: Available treatment options include C1-Inhibitor Replacement Therapy, Bradykinin B2 Receptor Antagonists, and Antifibrinolytic Agents. **Q: What is the projected market size for C1-Inhibitor Replacement Therapy by 2035?** A: The projected market size for C1-Inhibitor Replacement Therapy is expected to reach 1.577 USD Billion by 2035. **Q: How does the route of administration impact the Bradykinin Mediated Angioedema Market?** A: The route of administration includes Subcutaneous, Intravenous, and Oral, with Subcutaneous expected to reach 1.615 USD Billion by 2035. **Q: What demographic segments are considered in the Bradykinin Mediated Angioedema Market?** A: Demographic segments include Pediatric Patients, Adult Patients, and Geriatric Patients, with Adult Patients projected to reach 1.949 USD Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/bradykinin-mediated-angioedema-market-36162*